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Purpose: Our purpose was to characterize the
occurrence of gastrointestinal (GI) events among
women on oral bisphosphonate therapy.
Methods: This was a retrospective cohort study
that used a United States (US) claims database. The
study period was from January 1, 2000, to December
31, 2011. The index date was the date of the ﬁrst oral
bisphosphonate (alendronate, ibandronate, or risedr-
onate) prescription and occurred between January 1,
2001, and December 31, 2010. The pre- and post-
index periods were the 1-year periods before and after
the index date, respectively. The analysis included
women with osteoporosis agedZ55 years at the index
date who were naive to all osteoporosis treatments
before the index date and were continuously enrolled
in the health plan for at least 1 year before and 1 year
after the index date. Patients with a diagnosis of
malignant neoplasm during the pre- or post-index
periods or a diagnosis of Paget disease anytime in the
claims history were excluded. The occurrence of GI
events (deﬁned as esophagitis; gastroesophageal reﬂux
disease; ulcer, stricture, perforation, or hemorrhage of
the esophagus; gastric, duodenal, or peptic ulcer; acute
gastritis; duodenitis; GI hemorrhage; nausea/vomiting;
or dysphagia) was assessed during the pre-index
period and at 3, 6, and 12 months in the post-index
period. The rate of GI events was deﬁned as the
percentage of patients having at least 1 GI event in
each analysis period (ie, pre-index and post-index
periods). GI events in the post-index period were also
stratiﬁed by the presence of GI events in the pre-index
period.
Findings: A total of 75,593 women were included
in the analysis. The average age at the index date was
64.4 years. Gastroprotective agents were used by122817.9% of patients. Approximately one fourth of
patients (26.6%; n ¼ 20,073) had Z1 GI events in
the pre-index period. Approximately the same pro-
portion of patients (28.0%; n ¼ 21,142) experienced
GI events in the post-index period. The cumulative
rate of GI events during the post-index period was
higher among patients who had GI events in the pre-
index period (51.2%) than among patients without a
GI event in the pre-index period (19.6%).
Implications: Among women with osteoporosis
enrolled in a US commercial plan, GI events were
common regardless of bisphosphonate use. Approx-
imately one fourth of US women on bisphosphonate
therapy experienced GI events within the year after
initiation of therapy, and one half of US women with
a previous GI event had another event while taking
bisphosphonates. (Clin Ther. 2015;37:1228–1234)
& 2015 The Authors. Published by Elsevier HS
Journals, Inc.
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osteoporosis.INTRODUCTION
Approximately 15% of women in the United States
(US) aged Z50 years have osteoporosis,1,2 a skeletal
disease characterized by loss of bone density and
associated with an increased risk of fracture.3,4 AnVolume 37 Number 6
A. Modi et al.estimated 30% of women in this age range have a
high enough risk of osteoporotic fracture to be
considered eligible for pharmacologic treatment.5
Many therapies are available with proven efﬁcacy for
reducing fracture risk in patients with osteoporosis.
Among them, the oral bisphosphonates, including
alendronate, risedronate, and ibandronate, are the
most commonly used agents.
Oral bisphosphonates can cause irritation of the
gastrointestinal (GI) tract6; however, the clinical
relevance of endoscopic ﬁndings is uncertain.7
Clinical trials have found that upper GI adverse
events are no more frequent in bisphosphonate users
than in recipients of placebo,8–10 and several observa-
tional studies have found that GI events are as common
before bisphosphonate use as after.11–13 Studies of the
frequency of GI events among patients who used oral
bisphosphonates in real-world clinical practice have
found that the experience of a GI event increases the
likelihood of discontinuation,14,15 and discontinuation
precludes the reduction of fracture risk.
However, the understanding of the occurrence of
GI events and characterization of GI events among
patients who used oral bisphosphonates, particularly
in the US-managed care population, is limited. It is
important for treating physicians to know how many
bisphosphonate users, and which ones, will experi-
ence GI events so that they can be ready with
educational support and regimen adjustments to help
these patients maintain their reduction in osteopo-
rosis fracture risk. The objective of this study was
therefore to determine the proportion and character-




The retrospective cohort study was conducted with
the i3 InVision Data Mart (i3, Ann Arbor, Michigan;
now the Clinformatics Data Mart; Optum, Eden
Prairie, Minnesota). This large, nationwide US claims
database contains de-identiﬁed patient information,
including demographic characteristics and medical
and pharmacy claims data. Medical claims include
International Classiﬁcation of Diseases, Ninth Revi-
sion, Clinical Modiﬁcation (ICD-9-CM) diagnosis and
procedure codes. The outpatient pharmacy claims
data contain National Drug Codes for dispensed
medications. More than 3 million patients with aJune 2015diagnosis of osteoporosis, osteoporosis-related frac-
ture, and/or a prescription for a medication used to
treat or prevent osteoporosis were included in the
database during the study period from January 2000
through December 2011.
Study Design
The index date, which could occur any time
between January 1, 2001, and December 31, 2010,
was deﬁned as the date of the ﬁrst oral bisphospho-
nate prescription. The pre-index period was the
12 months before the index date, and the post-index
period was the 12 months after the index date. The
analyses used de-identiﬁed patient data; thus, in-
formed consent was not required.
Study Sample
Eligible patients were women aged Z55 years with
a diagnosis of osteoporosis (ICD-9 code 733.0), 1 new
pharmacy claim for an oral bisphosphonate (alendr-
onate, risedronate, or ibandronate) on the index date,
and continuous enrollment in the health plan during
the pre- and post-index periods. Patients were ex-
cluded if they had a pharmacy claim for any osteopo-
rosis therapy at any time during the pre-index claims
history, a medical claim for Paget disease (ICD-9 code
731.0x) at any time during the claims history, or
a diagnosis of malignant neoplasm (ICD-9 codes
140.xx–171.xx, 174.xx–208.xx, or 230.xx–239.xx)
during the pre- or post-index periods.
Study Variables
Patient age was assessed on the index date. Char-
acteristics assessed within 1 year before the index date
were the Deyo-Charlson comorbidity index score16
and the use of gastroprotective agents, gluco-
corticoids, estrogen, and NSAIDs. Disease diagnoses
and comorbidities were identiﬁed on the basis of ICD-
9 codes, and medications were identiﬁed on the basis
of National Drug Code numbers. Similar to previous
publications,12,13 GI events were identiﬁed on the
basis of ICD-9 diagnosis codes for esophagitis; gastro-
esophageal reﬂux disease; ulcer, stricture, perforation,
or hemorrhage of the esophagus; gastric, duodenal, or
peptic ulcers; acute gastritis; duodenitis; GI hemor-
rhage; nausea/vomiting; or dysphagia. The following
codes were deﬁned as severe GI events: 530.21 (ulcer
of the esophagus with bleeding), 530.4 (perforation of
esophagus), 530.82 (esophageal hemorrhage), 531.x1229
2,386,670
Female patients with osteoporosis
617,989
Patients with a pharmacy claim for oral 
osteoporosis  therapy
378,233
Patients aged ≥55 years old as of the index date
154,821
Patients with continuous eligibility 12 months before 
and after the index date
118,329
Patients with no medical claim for Paget’s disease 
or malignant neoplasms
97,109
Patients initiating a single drug on the index date
75,645
Patients whose index drug is a bisphosphonate
75,593
Patients receiving alendronate, ibandronate, or 
risedronate as the index drug
Figure 1. Patient selection.
Clinical Therapeutics(acute or chronic gastric ulcer with hemorrhage and/
or perforation), 532.x (acute or chronic duodenal
ulcer with hemorrhage and/or perforation), 533.x
(acute or chronic peptic ulcer with hemorrhage and/
or perforation), 535.0x (acute gastritis), and 578.xx
(GI hemorrhage).
Statistical Analysis
Patient characteristics and GI event rates were
analyzed descriptively. Pre-index patient character-
istics were assessed in all patients and compared for
patients with versus without post-index GI events.
Means and SDs were used for continuous variables,
and numbers and percentages were used for catego-
rical variables. Between-cohort differences were as-
sessed with t tests for continuous variables and χ2 tests
for categorical variables. The between-cohort differ-
ence was considered statistically signiﬁcant if the P
value was r0.05.
The primary outcome of interest was the rate of GI
events, which is presented for the pre-index period as
the percentage of patients who experienced an event
during the 12 months before the index date and, for
the post-index period, as the cumulative percentage of
patients who experienced GI events at 3, 6, and 12
months after the index date. In addition, the cumu-
lative 3-, 6- and 12-month GI event rates were
calculated and reported after stratiﬁcation by the
presence of pre-index GI events
RESULTS
Characteristics of the Study Population
After application of the inclusion and exclusion
criteria, 75,593 women were eligible for the analysis
(Figure 1). The average age at the index date was 64
years, and 17.9% of patients used gastroprotective agents
during the pre-index period (Table). One quarter of the
women (25.1%) used NSAIDs (Table). Use of
gastroprotective agents in the pre-index period was
signiﬁcantly higher in patients who experienced post-
index GI events (34.3% vs 11.5% in patients without
post-index GI events; P o 0.001; Table). Likewise, a
history of NSAID use, glucocorticoid use, and estrogen
use was more common in patients with post-index GI
events (30.9%, 22.1%, and 22.2%, respectively) than in
patients without post-index GI events (22.9%, 15.5%,
and 21.0%, respectively; all, Po 0.001; Table). Patients
with post-index GI events had a higher comorbidity score
than patients without GI events (0.8 vs 0.5; P o 0.001;1230Table). GI events ranged from mild symptoms such as
heartburn to serious events such as perforation of the
esophagus, stomach, or duodenum.Rate of GI Events
A total of 20,073 women (26.6%) had at least 1 GI
event in the pre-index period, and 21,142 women
(28.0%) had at least 1 GI event in the post-index
period. Severe GI events occurred in 2707 women in
the pre-index period (3.6%) and in 2966 women in
the post-index period (3.9%). Pre-index GI events hadVolume 37 Number 6





GI Events (N ¼ 21,142)
Patients Without Post-Index
GI Events (N ¼ 54,451)
Age, mean (SD), y 64.4 (8.4) 64.9 (8.5) 64.3 (8.4)*
CCI score, mean (SD) 0.56 (1.02) 0.8 (1.2) 0.5 (0.9)*
Age distribution, n (%)
55–59 y 27,820 (36.8) 7267 (34.4) 20,553 (37.8)*
60–69 y 28,770 (38.1) 8223 (38.9) 20,547 (37.7)*
70–79 y 12,038 (15.9) 3558 (16.8) 8480 (15.6)*
Z80 y 6965 (9.2) 2094 (9.9) 4871 (9.0)*
Medication use, n (%)
Gastroprotective agents 13,523 (17.9) 7254 (34.3) 6269 (11.5)*
Proton pump inhibitors 11,222 (14.9) 6279 (29.7) 4943 (9.1)*
H2 antagonists 2596 (3.4) 1243 (5.9) 1353 (2.5)*
Cytoprotectants 790 (1.1) 399 (1.9) 391 (0.7)*
NSAIDs 18,985 (25.1) 6539 (30.9) 12,446 (22.9)*
Glucocorticoids 13,094 (17.3) 4679 (22.1) 8415 (15.5)*
Estrogen 16,116 (21.3) 4700 (22.2) 11,416 (21.0)*
Pre-index GI events, n (%) 20,073 (26.6) 10,276 (48.6) 9797 (18.0)*
Severe pre-index GI events, n (%) 2707 (3.6) 1380 (6.5) 1327 (2.4)*
CCI ¼ Charlson comorbidity index; GI ¼ gastrointestinal.






































Pre-index GI events (N=20,073)
No pre-index GI events (N=55,520)
Figure 2. Percentage of patients who experi-
enced a GI event during the post-
index period. GI ¼ gastrointestinal.
A. Modi et al.occurred in 48.6% of patients with a GI event in
the post-index period, compared with 18.0% of
patients without a post-index GI event (P o 0.001;
Table). The proportion of patients with severe
pre-index GI events was higher among patients with
post-index GI events than among patients without
post-index GI events (6.5% vs 2.4%; P o 0.001;
Table).
Figure 2 shows the rate of GI events at
predetermined time points within the post-index pe-
riod. In the total study population, 10.7%, 17.5%,
and 28.0% experienced GI events within the ﬁrst 3, 6,
and 12 months, respectively, of bisphosphonate ini-
tiation. Totals of 903 (1.2%), 1653 (2.2%), and 2966
(3.9%) women experienced severe GI events at these
respective time points. The frequencies were higher
in women who had experienced GI events in the
pre-index period (23.0%, 35.3%, and 51.2%, respec-
tively) than in women with no GI events in the
pre-index period (6.3%, 11.1%, and 19.6%,
respectively).June 2015DISCUSSION
This study found that, in US women who initiated
bisphosphonate therapy, the overall rate of GI events
after initiating bisphosphonates is approximately the
same as before initiation. Post-initiation GI events1231
Clinical Therapeuticsoccurred more frequently in patients with a history of
GI events.
GI symptoms are common in populations with
osteoporosis, making it difﬁcult to distinguish back-
ground GI symptoms from those caused by medica-
tion use. In a survey of 497 women from the New
York City area, 47% of postmenopausal women
reported having upper GI symptoms (compared with
42% of perimenopausal women and 26% of preme-
nopausal women).17 The US Upper Gastrointestinal
Study (N ¼ 9076 women) found that 21% of adult
women experienced heartburn on a monthly basis.18
Vestergaard et al19 reported that Danish patients who
started various osteoporosis therapies were already at
increased risk of GI events, such as esophagitis,
esophageal ulceration/perforation, and gastroduo-
denal ulcers, before taking the medications.
Similarly, several US observational studies that
reported both pre-initiation and post-initiation GI
event rates found that the rate in the pre-initiation
period was similar to (or greater than) that in the
period of bisphosphonate use.11–13 Our results are
consistent with these data.
The rate of GI events among women treated with
osteoporosis therapy in our study population (28.0%)
was higher than that reported in previous US studies
of bisphosphonate users.11–14,20,21 Values in those
studies ranged from o1% for severe GI events13
and hospitalization for upper GI bleeding20 to 14%
when milder GI symptoms (heartburn, nausea, and/or
stomachache) were reported.14 Differences in sex
distribution (ie, percentage of men), the deﬁnition of
GI events, and the speciﬁc bisphosphonate(s) being
assessed likely contributed to the differences in the
results. Studies of postmenopausal women treated
with bisphosphonates in various European countries,
however, have reported GI event frequencies in the
range of 9.9% to 51.6%,22–26 indicating that our
ﬁndings are plausible.
Our observation that GI events among women
treated with osteoporosis therapy are more common
in patients with a history of GI events conﬁrms the
ﬁndings of several previous studies. Among UK
women taking risedronate, the rates of upper GI
adverse effects in women with and without pretreat-
ment GI problems were 32% and 11%, respectively
(P o 0.002).22 In another UK population that
switched from risedronate to alendronate, a history
of upper GI events was associated with a 43-fold1232increased risk of emergent upper GI events (hazard
ratio ¼ 3.18; 95% CI, 2.79–3.63).27 A Grecian cohort
who took alendronate exhibited more than twice the
odds of GI-related adverse events if they had a history
of GI disease (odds ratio ¼ 2.4; 95% CI, 1.4–3.8).28
Similarly, our ﬁnding that patients with post-index GI
events were more frequent users of NSAIDs and
glucocorticoids is consistent with previous analyses
ﬁnding that use of these drugs was predictive of GI
events.29,30
Limitations of our study design include the typical
weaknesses of claims database analyses, such as
potential coding errors/omissions and the assumption
of compliance on the basis of prescription reﬁlls. In
addition, our combined analysis of different bi-
sphosphonates does not take into account their indi-
vidual tolerability proﬁles. We report here an average
effect of the drug class as a whole. Our study
population did not include a control group, so we
cannot quantitatively distinguish between the compet-
ing factors that may be responsible for the relatively
stable GI event rates before and after bisphosphonate
initiation. Likewise, we cannot say whether the GI
event rates in an untreated control group would have
remained stable. Finally, the deﬁnition of GI events
differs across studies, and, as suggested in the third
paragraph of this Discussion, the event rate will vary
according to the severity of GI events.CONCLUSIONS
This study found that GI events are common among
women with osteoporosis both before and during
bisphosphonate use. Among US women enrolled in a
commercial health plan and taking bisphosphonate
therapy, one fourth experienced a GI event within a
year. Approximately one half of US women with a
previous GI event had another event while taking
bisphosphonates. Prescribing physicians should tar-
get their patients with a history of GI events for
follow-up about their treatment experience, and
future studies should evaluate the burden of GI
events as it relates to resource use in the osteoporotic
patient population.ACKNOWLEDGMENTS
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